News

The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.
The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...
"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...
We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making ...
DUPIXENT can cause allergic reactions that can sometimes be severe. Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following signs or ...
Dupixent now approved to treat five diseases with underlying type 2 inflammation in the EU. TARRYTOWN, N.Y. and PARIS, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ ...
AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and psoriasis driven by Th17 inflammation. However, newer research has shown ...
Sees "low single digit" percentage core EPS growth, FX adjusted Established MS pill faces competition from cheaper products Shares down 3%, lowest since mid-November CEO says Dupixent "mega ...
Dupixent included in list of overseas approved drugs that meet urgent clinical need in China. Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the National Medical Products ...
Dupixent is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation, including diseases of the skin, gut, and respiratory system that affect a broad range of ...